Literature DB >> 33489635

Development of Acquired Factor V Inhibitor After Surgical Procedure Without the Use of Fibrin Tissue Adhesives: A Case Report.

Hirohisa Hirata1, Yoshihiko Sakurai2, Tomohiro Takeda3, Tetsuya Kasetani1, Takeshi Morita1.   

Abstract

Development of acquired factor V (FV) inhibitor is a rare coagulation disorder. Production of heteroantibodies against bovine FV, a contaminant in fibrin tissue adhesives, is a common cause of this condition in the field of surgery. The development of recombinant thrombin eliminated contamination of bovine FV, and infrequent use of bovine thrombin has decreased the risk of FV inhibitor development. Here, we report the case of a 43-year-old man who had marked prolongation of prothrombin time and activated partial thromboplastin time after surgery. Mixing coagulation studies with normal plasma and patient's plasma suggested the presence of an inhibitor. Clotting factor assays revealed that FV activity decreased to <1% with positive FV inhibitor titer (9.2 Bethesda units). The diagnosis of the FV inhibitor was confirmed. Overt bleeding was not observed during the course of hospitalization. His coagulation abnormalities rapidly normalized without any medical intervention. A careful review of his medical records revealed that no tissue adhesives were used in the patient, and the FV inhibitor would likely be autoantibodies. Antibiotic use during the perioperative period or the surgical procedure itself may trigger the occurrence of FV inhibitors. This case highlights that FV inhibitor may develop after the surgical procedure even without a history of the use of fibrin tissue adhesives. Surgeons and hematologists should be aware that this rare but potentially life-threatening condition may occur after the surgical procedure.
Copyright © 2021, Hirata et al.

Entities:  

Keywords:  autoantibody; bovine thrombin; cross-mixing test; factor v; heteroantibody; inhibitor; tissue adhesive

Year:  2021        PMID: 33489635      PMCID: PMC7813542          DOI: 10.7759/cureus.12708

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  19 in total

Review 1.  Clinical and laboratory manifestations of anti-factor V antibodies.

Authors:  T L Ortel
Journal:  J Lab Clin Med       Date:  1999-04

2.  Thrombotest. A new method for controlling anticoagulant therapy.

Authors:  P A OWREN
Journal:  Lancet       Date:  1959-11-07       Impact factor: 79.321

3.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

4.  Fibrin glue.

Authors:  H I Atrah
Journal:  BMJ       Date:  1994-04-09

5.  Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin.

Authors:  J L Zehnder; L L Leung
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

6.  Infection, vaccines and other environmental triggers of autoimmunity.

Authors:  Vered Molina; Yehuda Shoenfeld
Journal:  Autoimmunity       Date:  2005-05       Impact factor: 2.815

Review 7.  Acquired factor V inhibitor. A problem-based systematic review.

Authors:  Ai Leen Ang; Ponnudurai Kuperan; Chin Hin Ng; Heng Joo Ng
Journal:  Thromb Haemost       Date:  2009-05       Impact factor: 5.249

Review 8.  Stress as a trigger of autoimmune disease.

Authors:  Ljudmila Stojanovich; Dragomir Marisavljevich
Journal:  Autoimmun Rev       Date:  2007-11-29       Impact factor: 9.754

9.  Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V.

Authors:  H Bänninger; T Hardegger; A Tobler; A Barth; P Schüpbach; W Reinhart; B Lämmle; M Furlan
Journal:  Br J Haematol       Date:  1993-11       Impact factor: 6.998

10.  Acquired factor V deficiency in a patient with a urinary tract infection presenting with haematuria followed by multiple haemorrhages with an extremely low level of factor V inhibitor: a case report and review of the literature.

Authors:  Xiangyu Wang; Xuemei Qin; Yuan Yu; Ran Wang; Xinguang Liu; Min Ji; Minran Zhou; Chunyan Chen
Journal:  Blood Coagul Fibrinolysis       Date:  2017-06       Impact factor: 1.276

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.